Lord Abbett & CO. LLC increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 286.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 733,291 shares of the biotechnology company’s stock after buying an additional 543,443 shares during the quarter. Lord Abbett & CO. LLC owned about 1.67% of Repligen worth $38,674,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. First Hawaiian Bank bought a new position in shares of Repligen in the 4th quarter valued at $28,000. Enlightenment Research LLC acquired a new stake in Repligen during the 4th quarter worth about $42,000. Parallel Advisors LLC grew its holdings in Repligen by 485.1% during the 4th quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 1,043 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Repligen in the 4th quarter valued at about $110,000. Finally, Pacer Advisors Inc. acquired a new stake in shares of Repligen in the 3rd quarter valued at about $116,000. 90.66% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:RGEN opened at $59.17 on Friday. The company has a market cap of $2.62 billion, a PE ratio of 81.05, a PEG ratio of 4.07 and a beta of 1.09. Repligen Co. has a 52 week low of $34.05 and a 52 week high of $70.50.
Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.21. The business had revenue of $51.90 million for the quarter, compared to the consensus estimate of $50.27 million. Repligen had a net margin of 8.56% and a return on equity of 5.51%. The company’s quarterly revenue was up 24.8% on a year-over-year basis. During the same period last year, the firm earned $0.20 earnings per share. As a group, sell-side analysts forecast that Repligen Co. will post 0.83 EPS for the current year.
Several research firms have commented on RGEN. Zacks Investment Research raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. BidaskClub lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, CL King upgraded shares of Repligen from a “neutral” rating to a “buy” rating in a research note on Monday, December 17th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $59.20.
In other news, CFO Jon Snodgres sold 2,645 shares of Repligen stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $58.52, for a total value of $154,785.40. Following the transaction, the chief financial officer now owns 29,646 shares of the company’s stock, valued at approximately $1,734,883.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt sold 7,475 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $59.01, for a total transaction of $441,099.75. Following the sale, the chief executive officer now directly owns 250,132 shares in the company, valued at approximately $14,760,289.32. The disclosure for this sale can be found here. Insiders sold a total of 27,731 shares of company stock valued at $1,625,768 over the last three months. Corporate insiders own 1.40% of the company’s stock.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Recommended Story: Momentum Investing
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.